MCID: ORL012
MIFTS: 47

Oral Leukoplakia

Categories: Oral diseases, Rare diseases

Aliases & Classifications for Oral Leukoplakia

MalaCards integrated aliases for Oral Leukoplakia:

Name: Oral Leukoplakia 53 29
Leukoplakia, Oral 73
Leukoplakia Oral 55

Classifications:



External Ids:

UMLS 73 C0023532

Summaries for Oral Leukoplakia

NIH Rare Diseases : 53 Oral leukoplakia describes a white plaque that does not rub off and cannot be characterized as any other condition. Though it may occur in any part of the mouth, it generally affects the tongue, gums, and inner cheek. Physicians will usually biopsy oral leukoplakia lesions as 20-40% of cases are precancerous or cancerous at the time of biopsy and another 8-15% become cancerous over time. The exact cause of oral leukoplakia is not known. Factors that may increase the risk of developing oral leukoplakia include smoking, alcohol use, vitamin deficiencies, malocclusion, and a weakened immune system.Treatment depends on the biopsy results and the size, appearance, and location of the oral leukoplakia. Removal or ablation of the lesion by surgery, laser, or cryotherapy (use of low temperature) may be recommended.

MalaCards based summary : Oral Leukoplakia, also known as leukoplakia, oral, is related to leukoplakia and oral submucous fibrosis. An important gene associated with Oral Leukoplakia is GSTM1 (Glutathione S-Transferase Mu 1), and among its related pathways/superpathways are Regulation of TP53 Activity and Pathways in cancer. The drugs Rosiglitazone and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include tongue, bone and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Oral Leukoplakia

Diseases related to Oral Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 31.3 GSTM1 GSTT1 MKI67 PCNA
2 oral submucous fibrosis 30.7 GSTM1 GSTT1
3 squamous cell carcinoma 30.6 CDKN2A MKI67 TP53 TP63 XRCC1
4 verrucous carcinoma 30.2 CDKN2A TP53
5 in situ carcinoma 29.8 CDKN2A TP53
6 oral cancer 29.8 CDKN2A GSTM1 GSTT1 PCNA TP53
7 esophageal cancer 29.8 CDKN2A GSTM1 GSTT1 TP53
8 papilloma 29.8 CDKN2A PCNA TP53 TP63
9 oral cavity cancer 29.7 GSTM1 GSTT1 TP53
10 basal cell carcinoma 28.7 CDKN2A GSTM1 GSTT1 MKI67 TP53 TP63
11 proliferative verrucous leukoplakia 12.0
12 oral hairy leukoplakia 11.8
13 dyskeratosis congenita 11.6
14 revesz syndrome 11.3
15 oral mucosa leukoplakia 11.3
16 dyskeratosis congenita, autosomal recessive 5 11.1
17 dyskeratosis congenita, autosomal recessive 6 11.1
18 dyskeratosis congenita, autosomal dominant 6 11.1
19 oral squamous cell carcinoma 10.7
20 lichen planus 10.5
21 oral lichen planus 10.3
22 brain ependymoma 10.2 MKI67 TP53
23 adenosarcoma 10.2 MKI67 TP53
24 soft tissue sarcoma 10.2 MKI67 TP53
25 non-proliferative fibrocystic change of the breast 10.2 TP53 XRCC1
26 embryonal sarcoma 10.2 MKI67 TP53
27 bladder squamous cell carcinoma 10.2 CDKN2A TP53
28 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
29 bladder carcinoma in situ 10.2 CDKN2A TP53
30 vulva squamous cell carcinoma 10.2 CDKN2A TP53
31 scrotal carcinoma 10.2 CDKN2A TP53
32 vulvar disease 10.2 CDKN2A TP53
33 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
34 bartholin's gland disease 10.2 CDKN2A TP53
35 anal squamous cell carcinoma 10.2 CDKN2A TP53
36 megaesophagus 10.1 CDKN2A TP53
37 glycogen-rich clear cell breast carcinoma 10.1 CDKN2A TP53
38 gastric adenosquamous carcinoma 10.1 CDKN2A TP53
39 keratocystic odontogenic tumor 10.1 MKI67 TP53
40 adenosquamous carcinoma 10.1 TP53 TP63
41 anogenital venereal wart 10.1 CDKN2A TP53
42 cervix uteri carcinoma in situ 10.1 CDKN2A TP53
43 uterus carcinoma in situ 10.1 CDKN2A TP53
44 meningeal melanomatosis 10.1 CDKN2A TP53
45 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.1 TP53 TP63
46 dedifferentiated liposarcoma 10.1 CDKN2A TP53
47 endocervical adenocarcinoma 10.1 CDKN2A TP53
48 penile disease 10.1 CDKN2A TP53
49 ulcerative stomatitis 10.1 TP53 TP63
50 cervix small cell carcinoma 10.1 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Leukoplakia:



Diseases related to Oral Leukoplakia

Symptoms & Phenotypes for Oral Leukoplakia

GenomeRNAi Phenotypes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CDKN2A PCNA TP53 XRCC1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CDKN2A PCNA TP53 TP63 XRCC1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.26 PCNA TP53 TP63 XRCC1

MGI Mouse Phenotypes related to Oral Leukoplakia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.1 CDKN2A MKI67 PCNA TINF2 TP53 TP63

Drugs & Therapeutics for Oral Leukoplakia

Drugs for Oral Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
2
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
3
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
4
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
5
Trioxsalen Approved Phase 2 3902-71-4 5585
6
Metformin Approved Phase 2 657-24-9 14219 4091
7
Pembrolizumab Approved Phase 2 1374853-91-4
8
Maleic acid Experimental Phase 2 110-16-7 444266
9
Fenretinide Investigational Phase 2 65646-68-6
10 Hypoglycemic Agents Phase 2
11 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
12 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
13 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
14 Cyclooxygenase 2 Inhibitors Phase 2
15 Cyclooxygenase Inhibitors Phase 2,Phase 1,Not Applicable
16 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
18 Analgesics Phase 2,Phase 1,Not Applicable
19 Retinamide Phase 2
20 Dermatologic Agents Phase 1, Phase 2,Phase 2
21 Photosensitizing Agents Phase 1, Phase 2,Phase 2
22 Pharmaceutical Solutions Phase 1, Phase 2
23 Hematoporphyrins Phase 2
24 Dihematoporphyrin Ether Phase 2
25 Hematoporphyrin Derivative Phase 2
26 Ether Phase 2
27 Tea Phase 2
28
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
29 Platelet Aggregation Inhibitors Phase 1
30 Antipyretics Phase 1
31 Fibrinolytic Agents Phase 1
32
Heparin Approved, Investigational 9005-49-6 772 46507594
33
Sulindac Approved, Investigational Not Applicable 38194-50-2 5352 1548887
34 calcium heparin
35 Coagulants
36 Hemostatics ,Not Applicable
37 Tolonium Chloride

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
3 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00099021 Phase 2 pioglitazone hydrochloride
4 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
5 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
6 Fenretinide in Treating Patients With Leukoplakia of the Mouth Completed NCT00004161 Phase 2 fenretinide;Placebo
7 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
8 Treatment of Oral Premalignant Lesions With 5-ALA PDT Completed NCT00571974 Phase 1, Phase 2 5-Aminolevulinic Acid (Levulan KerastickTM)
9 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Completed NCT00453336 Phase 2 Porfimer Sodium
10 Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
11 Pembrolizumab in Treating Participants With Leukoplakia Not yet recruiting NCT03603223 Phase 2
12 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2 Lozenge Intake
13 Pioglitazone for Oral Premalignant Lesions Terminated NCT00951379 Phase 2 Pioglitazone hydrochloride
14 Aspirin Mouthwash in Treating Patients With Oral Leukoplakia Completed NCT01238185 Phase 1 acetylsalicylic acid
15 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1 aminolevulinic acid hydrochloride;photodynamic therapy
16 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
17 Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity Unknown status NCT01636544 Not Applicable
18 Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia Completed NCT03233165 Not Applicable
19 Biomarkers for Oral Cancer Completed NCT00341497
20 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Completed NCT03031899
21 Clinical Research Core Dental Screening Protocol Completed NCT00090818
22 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia Completed NCT00835341
23 A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery Recruiting NCT01355926 Not Applicable
24 A Randomized Study of Sulindac in Oral Premalignant Lesions Active, not recruiting NCT00299195 Not Applicable sulindac;Placebo
25 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Not yet recruiting NCT03682562

Search NIH Clinical Center for Oral Leukoplakia

Genetic Tests for Oral Leukoplakia

Genetic tests related to Oral Leukoplakia:

# Genetic test Affiliating Genes
1 Oral Leukoplakia 29

Anatomical Context for Oral Leukoplakia

MalaCards organs/tissues related to Oral Leukoplakia:

41
Tongue, Bone, Lung, Bone Marrow, Brain, Cervix, Thyroid

Publications for Oral Leukoplakia

Articles related to Oral Leukoplakia:

(show top 50) (show all 562)
# Title Authors Year
1
Determination and diagnostic value of CA9 mRNA in peripheral blood of patients with oral leukoplakia. ( 29745265 )
2018
2
Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma. ( 29620248 )
2018
3
CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma. ( 29805639 )
2018
4
A clinical diagnosis of oral leukoplakia; A guide for dentists. ( 29274164 )
2018
5
Immunoexpression of SOX-2 in oral leukoplakia. ( 29938872 )
2018
6
Knowledge about oral leukoplakia for use at different levels of expertise, including patients. ( 29480645 )
2018
7
Liquid-based oral brush cytology in the diagnosis of oral leukoplakia using a modified Bethesda Cytology system. ( 29957892 )
2018
8
Oral leukoplakia remains a challenging condition. ( 29480606 )
2018
9
T cells are involved in the induction of macrophage phenotypes in oral leukoplakia and squamous cell carcinoma-a preliminary report. ( 29108105 )
2018
10
Malignant transformation of Taiwanese patients with oral leukoplakia: A nationwide population-based retrospective cohort study. ( 29428194 )
2018
11
Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia. ( 29588189 )
2018
12
Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation. ( 29928356 )
2018
13
Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. ( 29436667 )
2018
14
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment. ( 29443777 )
2018
15
Mature dendritic cell density is affected by smoking habit, lesion size, and epithelial dysplasia in oral leukoplakia samples. ( 30056280 )
2018
16
Low level laser therapy reduces oral leukoplakia lesion size: Results from a preliminary study. ( 30098877 )
2018
17
Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis. ( 30126398 )
2018
18
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. ( 30160018 )
2018
19
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer. ( 30172723 )
2018
20
Oral leukoplakia: A diagnostic challenge for clinicians and pathologists. ( 30203899 )
2018
21
A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. ( 30210912 )
2018
22
Treatment Outcome of Oral Leukoplakia with Er:YAG Laser: A 5-Year Follow-Up Prospective Comparative Study. ( 30339489 )
2018
23
Photodynamic therapy in the treatment of oral leukoplakia: a systematic review. ( 30391342 )
2018
24
Malignant transformation of oral leukoplakia treated with carbon dioxide laser: a meta-analysis. ( 30443884 )
2018
25
Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. ( 28923296 )
2017
26
Expression of Human Papillomavirus DNA and p53 Polymorphisms through Polymerase Chain Reaction in Normal Mucosa and Oral Leukoplakia Individuals with Deleterious Oral Habits. ( 28584747 )
2017
27
Correlation of Vascularization and Inflammation with Severity of Oral Leukoplakia. ( 29531547 )
2017
28
Different Expression of Aldehyde Dehydrogenases 1A1 and 2 in Oral Leukoplakia With Epithelial Dysplasia and in Oral Squamous Cell Carcinoma. ( 29189260 )
2017
29
In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. ( 28580171 )
2017
30
Plasma HPV DNA is detectable in oral leukoplakia patients. ( 28554767 )
2017
31
Oral leukoplakia and proliferative verrucous leukoplakia: a review for dental practitioners. ( 29097794 )
2017
32
Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers. ( 28797449 )
2017
33
Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. ( 28904918 )
2017
34
Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 28862226 )
2017
35
Effects of Black Raspberry Extract and Berry Compounds on Repair of DNA Damage and Mutagenesis Induced by Chemical and Physical Agents in Human Oral Leukoplakia and Rat Oral Fibroblasts. ( 29068672 )
2017
36
Micronucleus Assay: An Early Diagnostic Tool to Assess Genotoxic Changes in Patients with Tobacco Use, Oral Leukoplakia and Oral Submucous Fibrosis. ( 29207828 )
2017
37
The Microbiome of Potentially Malignant Oral Leukoplakia Exhibits Enrichment for<i>Fusobacterium, Leptotrichia, Campylobacter</i>, and<i>Rothia</i>Species. ( 29250055 )
2017
38
Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia. ( 28511503 )
2017
39
Quantitative prediction of oral cancer risk in patients with oral leukoplakia. ( 28545021 )
2017
40
New definition proposed for oral leukoplakia. ( 28928786 )
2017
41
Limited evidence for interventions to treat oral leukoplakia. ( 29075031 )
2017
42
Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia. ( 28256094 )
2017
43
Evaluation of Different Laser-Supported Surgical Protocols for the Treatment of Oral Leukoplakia: A Long-Term Follow-Up. ( 28426376 )
2017
44
Oral leukoplakia and oral cavity squamous cell carcinoma. ( 28916027 )
2017
45
Ultrastructural Changes during the Life Cycle of<i>Mycoplasma salivarium</i>in Oral Biopsies from Patients with Oral Leukoplakia. ( 28983467 )
2017
46
PTEN allelic loss is an important mechanism in the late stage of development of oral leukoplakia into oral squamous cell carcinoma. ( 28858374 )
2017
47
Type of surgical treatment and recurrence of oral leukoplakia: A retrospective clinical study. ( 28809365 )
2017
48
Snail and Axin2 expression predict the malignant transformation of oral leukoplakia. ( 28939076 )
2017
49
Factors affecting Clinical Outcomes after Treatment of Oral Leukoplakia with CO2 and Diode Laser. ( 28874640 )
2017
50
Proliferative verrucous leukoplakia misdiagnosed as oral leukoplakia. ( 29551871 )
2017

Variations for Oral Leukoplakia

Expression for Oral Leukoplakia

Search GEO for disease gene expression data for Oral Leukoplakia.

Pathways for Oral Leukoplakia

Pathways related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 CDKN2A PCNA TP53 TP63
2 12.45 CDKN2A GSTM1 GSTT1 TP53
3
Show member pathways
12.34 CDKN2A GSTM1 GSTT1 TP53
4 12.24 CDKN2A TP53 TP63
5 12.15 CDKN2A PCNA TP53
6 12.09 CDKN2A PCNA TP53
7 11.72 GSTM1 GSTT1 TP53
8 11.62 PCNA TP53 TP63
9 11.57 CDKN2A MKI67 PCNA TP53 TP63 XRCC1
10 11.46 CDKN2A PCNA TP53
11 11.22 PCNA TP53
12 11.12 CDKN2A GSTM1 GSTT1 TP53
13 11.05 PCNA TP53
14 11.04 CDKN2A TP53
15 10.97 PCNA TP53
16 10.96 GSTM1 GSTT1
17 10.86 GSTM1 GSTT1
18 10.8 CDKN2A TP53
19
Show member pathways
10.67 CDKN2A TP53 TP63

GO Terms for Oral Leukoplakia

Cellular components related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.33 TP53 TP63 XRCC1
2 nuclear chromosome, telomeric region GO:0000784 9.13 PCNA TINF2 XRCC1
3 nuclear body GO:0016604 8.92 MKI67 PCNA TINF2 TP53

Biological processes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 glutathione metabolic process GO:0006749 9.49 GSTM1 GSTT1
2 base-excision repair GO:0006284 9.48 TP53 XRCC1
3 protein tetramerization GO:0051262 9.46 TP53 TP63
4 cell aging GO:0007569 9.43 TP53 TP63
5 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.4 TP53 TP63
6 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.37 TP53 TP63
7 nucleotide-excision repair, DNA gap filling GO:0006297 9.32 PCNA XRCC1
8 glutathione derivative biosynthetic process GO:1901687 9.26 GSTM1 GSTT1
9 cell proliferation GO:0008283 9.26 MKI67 PCNA TP53 TP63
10 replicative senescence GO:0090399 9.16 CDKN2A TP53
11 negative regulation of protein ADP-ribosylation GO:0010836 8.62 TINF2 XRCC1

Molecular functions related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.63 CDKN2A MKI67 PCNA TINF2 TP53 TP63
2 disordered domain specific binding GO:0097718 9.37 CDKN2A TP53
3 histone acetyltransferase binding GO:0035035 9.32 PCNA TP53
4 glutathione transferase activity GO:0004364 9.26 GSTM1 GSTT1
5 enzyme binding GO:0019899 9.26 GSTM1 PCNA TP53 XRCC1
6 damaged DNA binding GO:0003684 8.8 PCNA TP63 XRCC1

Sources for Oral Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....